Isavuconazonium
This prodrug is rapidly converted in the body to isavuconazole, a broad-spectrum antifungal medication used to treat serious invasive fungal infections caused by Aspergillus and Mucor species in patients with weakened immune systems. The prodrug formulation improves water solubility for intravenous administration.
Molecular Weight
717.8000 g/mol
LogP
4.10
TPSA
188.00 Ų
Lipinski RO5
Fail
Mechanism of Action
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D Structure
Cite this structure
Embed this structure
SMILES
CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1
InChI
InChI=1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1
Molecular Formula
C35H35F2N8O5S+
HBD / HBA
2 / 13
Rotatable Bonds
15
Heavy Atoms
51
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
This prodrug is rapidly converted in the body to isavuconazole, a broad-spectrum antifungal medication used to treat serious invasive fungal infections caused by Aspergillus and Mucor species in patients with weakened immune systems. The prodrug formulation improves water solubility for intravenous administration.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Isavuconazonium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1183349. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6918606. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="isavuconazonium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/isavuconazonium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/isavuconazonium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/isavuconazonium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="isavuconazonium"></drugfyi-drug>